Despite our novel finding regarding the dapagliflozin effect on diabetic HLI, it is noteworthy that SGLT2 inhibitors demonstrated different effects on diabetic-associated vascular complications, particularly their therapeutic effects on peripheral artery diseases (Dicembrini et al., 2019). The gene discussed is SLC5A2; the disease is peripheral arterial disease.